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GWASPreterm birth in the United States is now 12%. Multiple genes, gene networks, and variants have been asso-
ciated with this disease. Using a custom database for preterm birth (dbPTB) with a reﬁned set of genes exten-
sively curated from literature and biological databases, we analyzed GWAS of preterm birth for complete
genotype data on nearly 2000 preterm and term mothers. We used both the curated genes and a
genome-wide approach to carry out a pathway-based analysis. There were 19 signiﬁcant pathways, which
withstood FDR correction for multiple testing that were identiﬁed using both the curated genes and the
genome-wide approach. The analysis based on the curated genes was more signiﬁcant than genome-wide
in 15 out of 19 pathways. This approach demonstrates the use of a validated set of genes, in the analysis of
otherwise unsuccessful GWAS data, to identify gene–gene interactions in a way that enhances statistical
power and discovery.
© 2013 Elsevier Inc. All rights reserved.1. Introduction
Genome-wide association studies (GWAS) enable investigation of
the genetic associations underlying complex diseases without a priori
hypotheses [1,2]. Advances in high-throughput genotyping, sequenc-
ing technology and developments in computational power have
enhanced the feasibility of large case-controlled studies and reduced
costs [3]. Since they have the potential of identifying novel genetic
variants, GWAS have become a popular approach to the investigation
of complex diseases. By the second quarter of 2011, there were 1449
reports in the Catalog of Published Genome-Wide Association Studies
(http://www.genome.gov/gwastudies/) covering hundreds of associ-
ations of common genetic variants with complex traits [4]. These
reports have provided valuable insights into the genetic architecture
of disease, including inﬂammatory bowel disease, macular degenera-
tion, and obesity [5–7]. Nonetheless, GWAS for complex diseases have
had only a measured success. While, there have been many loci iden-
tiﬁed and replicated in GWAS, many studies have failed to identify
signiﬁcant associations. Likewise, the genetic markers that have
been identiﬁed through the GWAS approach are rarely functional
variants in the diseases with which they are associated. In addition,
most common variants that are identiﬁed by GWAS are responsible
for only a small portion of the genetic variation and thus there
remains a large amount of “missing heritability” [8,9]. If the “common
disease common variant hypothesis” underlying the GWAS approachomen & Infants Hospital, 101
453 7571.
rights reserved.does not explain the genetic contributions to complex diseases then
what does [8,10]? It is likely that rare variants and/or genetic interac-
tions, epistasis, underlie a signiﬁcant portion of the ‘missing heritabil-
ity’ not revealed by conventional GWAS analyses [11–13]. It is also
likely that complex mechanisms and higher orders of gene–gene
interactions underlie the pathogenesis of many (most) complex
diseases and lead to variations/alterations of the phenotype [14–17].
Identiﬁcation of multiple genes contributing to disease pathogenesis
may help in understanding the effects on phenotype and in the
search for missing heritability [18]. Nonetheless, the GWAS-based
interrogation of large numbers of anonymous single nucleotide poly-
morphisms (SNP) severely limits power, thus weakening our com-
putational ability to examine combinatorial gene–gene interactions
[19–21].
We are interested in the genetic contribution(s) to preterm
birth. Preterm birth is an important, poorly understood clinical
problem [22–25]. The incidence of preterm birth (PTB) in the
United States is now 12%, or 1 in 8 women [26]. It creates enormous
clinical, economic and psychological burdens. The pathogenesis has
remained elusive. Clinical tests and interventions to identify the
patients at risks for preterm birth have relied heavily on assessment
of common pathways associated with labor, such as myometrial
contractility, cervical ripening, and decidual/membrane activation
[27]. Interventions to prevent pretermbirth are aimed at these common
pathways. However, most of these interventions have proven ineffec-
tive. Multiple genes, gene networks, and variants have been associated
with preterm birth; however, single genes and pathways and simple
patterns of inheritance are inadequate to explain the pathogenesis of
the majority of preterm births [24]. The pathogenesis of PTB may be
164 A. Uzun et al. / Genomics 101 (2013) 163–170better understood if the analysis incorporated a more complex model
that entails a host of genes [25] and with environmental triggers
overlaying the genetics as well.
We have developed an approach for identifying a parsimonious
set of genes for the study of preterm birth validated by a priori bi-
ological information. We used a semantic data mining and natural
language processing approach to extract all published articles re-
lated to preterm birth [28]. Then, the genes identiﬁed from public
databases and archives of expression arrays were aggregated with
the gene set curated from the literature. Lastly, pathway analysis
was used to impute genes from pathways identiﬁed during
curation. The curated articles and collected genetic information
form a unique resource for investigators interested in preterm
birth, the Database for Preterm Birth (dbPTB), publicly-accessible
at http://ptbdb.cs.brown.edu/dbPTBv1.php. Recently, results from
a genome-wide study of preterm birth, “GENEVA,” became avail-
able in dbGAP [29]. The dataset includes phenotypic information
and complete genotype data on nearly 2000 mothers, ranging
from 20 to 42 weeks of gestation. Since it has been demonstrated
that the genetic risk of preterm birth segregates heavily to the ma-
ternal genome, we have concentrated our analysis only onmaternal ge-
notype information [30]. Using the curated genes from dbPTB, we have
analyzed the GENEVA data set frommothers only. The results of the re-
ﬁned curated genes were further analyzed by gene set enrichment
analysis.
2. Results
2.1. SNP basic association analysis
We applied standard case/control allelic testing in Plink v1.07 to
analyze the association of individual SNPs with preterm birth. In
the ﬁrst analysis, we only used SNPs that belonged to the curated
dbPTB genes [28]. We included SNPs within the genomic region
encompassing each gene as well as SNPs within 5 kb upstream or
downstream. Of the 617 genes identiﬁed in dbPTB, 551 were mapped
onto the Illumina 660 quad platform encompassing 9077 tag SNPs. In
the second analysis, we ran a genome-wide comparison using all of
the SNPs on the Illumina platform (n=560,768 SNPs). Preterm
women were divided into three gestational age categories: less
than 30 weeks of gestation (n=92), less than 34 weeks of gestation
(n=446), and less than 37 weeks of gestation (n=884) and
compared with women who delivered greater than or equal to
38 weeks of gestation (n=960). A Manhattan plot showing the re-
sults for all three preterm gestational age groups across the dbPTB
SNPs is shown in Fig. 1. As can be seen from this representative plot
of chromosome 1, there were multiple regions where associations
were seen for all three patient groups. Similar results were seen for
the other chromosomes. While several regions demonstrated − log P
values greater than 2.5 (Pb0.0032), no signiﬁcant single variants were
identiﬁed in the dbPTB set of curated genes that withstood Bonferroni's
correction for multiple comparisons (Pb5.5×10−6). The lowest
P-value was 1.45×10−4 for the SNP (rs5742637) which belongs to
insulin-like growth factor 1 gene (IGF1). In the genome-wide analysis
only a single variant reached the Bonferroni-corrected signiﬁcance
threshold (Pb8.9×10−8). The P-value for this SNP (rs12682166) was
4.99×10−8. This SNP did not map within any known gene nor were
there any geneswithin 5 kb upstream or downstream from this variant.
2.2. GSEA analysis of dbPTB genes
Gene set enrichment analysis was carried out using the 9077 SNPs
within the 515 curated dbPTB genes. We compared the cases less than
30 weeks of gestation with the controls described in the previous
section. For the GSEA analysis we selected the following analytical
options: tag SNPS with the 5 kb upstream and downstream of eachgene [31]; gene sets were selected, including “canonical pathways,
GO biological process, GO molecular function, GO cellular compo-
nent;” lastly, we used gene set size ranges from 5 to 200. For compar-
ison, we performed GSEA on the genome-wide SNP data (n=560,768
SNPs). All parameters were kept the same when running the genome
wide analysis.
From the dbPTB-based pathway analysis, we identiﬁed a total of 30
pathways with high conﬁdence values (false discovery rate correction
for multiple comparison, FDR, b0.05, see Supplemental Table 1. From
the whole genome based pathway analysis 39 pathways with high
conﬁdence were identiﬁed. When we compared the analyses, there
were 37 shared pathways. A view illustrating the pathway analysis
results for both analyses is shown in Fig. 2 and Table 1. The vertical
axis represents the− log P values for each of the pathways. The statis-
tical values for the pathways identiﬁed by dbPTB are shown in dark
blue and for the whole genome analysis are shown in light blue.
Each of the pathways is shown along the horizontal axis. The thresh-
old value of− log P=1.3 corresponds to an FDR P value less than 0.05
which has already been adjusted for multiple comparisons. There
were nineteen shared pathways that reached signiﬁcance by either
analysis. The dbPTB analysis showed greater signiﬁcance in 15 out of
the 19 shared signiﬁcant pathways (Fig. 2). There were 13 signiﬁcant
pathways that were only identiﬁed using the dbPTB curated set of
genes and 33 signiﬁcant pathways that were only identiﬁed in the
whole genome analysis. Remarkably, most of the pathways involving
inﬂammation were either shared or identiﬁed only by the dbPTB-
based pathway analysis (Supplemental Table 1). Prominent among
the results from the genome-wide analysis were metabolomic path-
ways including phospholipase A2 activity, amino acid derivative,
biosynthetic processes, plus the pathway involving the trans-Golgi
network, enzyme inhibitor pathway, lipase activity and nitrogen
compound biosynthetic processes and carboxyl esterase activity,
hypotaurine metabolism (Supplemental Table 2). A summary com-
parison of the results of the pathway analyses from both dbPTB and
the genome-wide data is shown in Supplemental Table 3 and Supple-
mental Fig. 1.
3. Discussion
Although there have been some successes, GWAS based ap-
proaches have failed to provide comprehensive explanations for the
genetic basis of many complex diseases [32]. There are many
challenges in identiﬁcation of the causative genes. As noted above
for complex diseases, gene–gene interactions are a far more likely
model as complex molecular networks and metabolic pathways are
involved in polygenic diseases [31,33–35]. For our approach, we
took into consideration the a priori biological information about
genes involved in preterm birth from the published literature and
from available expression arrays. In addition to these initial steps
we included pathway analysis to impute additional genes likely to
be involved from pathways identiﬁed during curation. Combining
these three sources powered the curated gene set for our disease of
interest, preterm birth [28]. We increased our power by focusing on
a smaller number of comparisons, none of the identiﬁed single gene
variants reached statistical signiﬁcance. By employing pathway
based permutation testing we identiﬁed important genes and their
variants in this important disorder. Moreover, by using a more
parsimonious, curated set of genes or variants with demonstrated
biological signiﬁcance, we greatly enhance our statistical power.
This was most evident in the statistical validation of pathways
involved in inﬂammation. Those pathways were not evident in the
genome wide analysis but were solely identiﬁed using the curated
set of genes for permutation testing.
Since a portion of the ‘missing heritability’ is likely explained by
gene–gene interactions, we employed a pathway-based approach to
analyze the results from the large GWAS on preterm birth [13]. Our
Fig. 1.Manhattan plots of three preterm gestational age groups. We analyzed the single SNP association with genes from dbPTB by comparing the controls (38 gestational weeks and
high) and three gestational groups (37, 34, and 30 gestational weeks or less). Manhattan plots showing the results for three preterm gestational age groups. The Y-axis indicates the−log
P value for each SNP, X-axis shows the genomic positions. A) Theﬁgure represents the comparison of groups for 38 gestational weeks or high vs. 30 gestational weeks or less. B) The ﬁgure
represents the comparison of groups for 38 gestationalweeks or high vs. 34 gestationalweeks or less. C) Theﬁgure represents the comparison of groups for 38 gestationalweeks or high vs.
37 gestational weeks or less.
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Fig. 2. Comparison of the pathway analysis results from dbPTB genes and from genome wide analysis. The vertical axis represents the −log P values for each the pathways. The
statistical values for dbPTB are shown in dark gray bars and for the whole genome analysis are shown in light gray bars. Each of the pathways is shown along the horizontal
axis. The threshold value of −log P=1.3 corresponds to an FDR P value less than 0.05 which has already been corrected for multiple comparisons.
166 A. Uzun et al. / Genomics 101 (2013) 163–170pathway-based approach used the SNPs selected for the dbPTB set of
genes and whole genome from GENEVA data. In order to enhance
our likelihood of success by selecting the most “extreme phenotype”,
we restricted our analysis to comparison of controls which deliveredTable 1
The signiﬁcant pathways from dbPTB in comparison to the analysis from the whole ge-
nome. The table shows the gene set FDR values of the signiﬁcant pathways from dbPTB
in comparison to the analysis from the whole genome. The threshold of FDRb0.25 de-
notes the conﬁdence of ‘possible’ or ‘hypothesis’, while the threshold of FDRb0.05 is
regarded as ‘high conﬁdence’ or ‘with statistical signiﬁcance’.
Gene sets Gene set FDR⁎
for dbPTB
Gene set FDR⁎
for whole genome
Arginine and proline metabolism 0.01625 0.15443571
Cardiac EGF pathway 0.059756756 0.20725532
Electron carrier activity 0.003333333 0.114043474
ERYTH pathway 0.04771875 0.032863636
Female pregnancy 0.015 0.15270229
GCR pathway 0.10168333 0.13590197
Glycerolipid metabolism 0.13772368 0.20964974
GSK3 pathway 0.0025 0.136
Fatty acid metabolism 0.032652173 0.23582296
Arginine and proline metabolism 0.20881133 0.054365855
Tyrosine metabolism 0.001 0.17828049
Glycerolipid metabolism 0.13772368 0.08272603
Glycerophospholipid metabolism 0.039499998 0.059211537
Arachidonic acid metabolism 0.13734783 0.24749328
P53 signaling pathway 0.20801903 0.22548293
Apoptosis 0.087419994 0.22546601
Tight junction 0.016727272 0.17913496
Toll like receptor signaling pathway 0.098 0.1351
Long term depression 0.059526317 0.055510636
Endometrial cancer 0.092660375 0.2393868
Glioma 0.082 0.22672947
Prostate cancer 0.04909091 0.24307871
Small cell lung cancer 0.001 0.08212857
Inﬂammatory response 0.15717977 0.17977108
Multi organism process 0.03808 0.023111112
Nitrogen compound metabolic process 0.12135385 0.2158209
RACCYCD pathway 0.21092594 0.08395946
RAS pathway 0.14021127 0.0081
Regulation of blood pressure 0.00725 0.11133333
Regulation of kinase activity 0.1786701 0.16406667
Regulation of protein kinase activity 0.1786701 0.15386029
Regulation of transferase activity 0.1786701 0.1796467
Response to biotic stimulus 0.025818182 0.048911765
Response to other organism 0.1394875 0.026736842
SIG PIP3 signaling in cardiac myocytes 0.020499999 0.048689652
Smooth muscle contraction 0.022105262 0.07357576
TEL pathway 0.049032256 0.065125at 38 weeks of gestation or higher to patients who delivered at
30 weeks of gestation or lower.
In order to generate the “P-values” needed for the pathway analy-
sis, we ﬁrst carried out single variant analysis using both dbPTB curat-
ed genes and whole genome data. As already noted, we did not ﬁnd
signiﬁcant single variant associated with any known genes using ei-
ther the dbPTB curated gene set or the genome-wide data. By compar-
ison, the pathway based approach yielded some rich and signiﬁcant
results which replicate the ﬁndings from other studies [24]. Among
the ranked list of SNPs in the dbPTB curated gene analysis, the best
SNP (rs5742637) mapped onto the IGF1 gene. IGF1 was identiﬁed in
the dbPTB gene set from a single manuscript which sought candidate
genes associated with coagulation and inﬂammatory pathways in
preterm birth [24]. In that report, 1536 SNPs in 130 candidate genes
were interrogated and IGF1 was one of the signiﬁcant ﬁndings. In
the pathway analysis, there were a total of 3 signiﬁcant pathways
which included IGF1. These included the erythrocyte differentiation
pathway, prostate cancer and PIP3 signaling in cardiac myocytes.
These overlap with the pathways in which IGF1 has been more broad-
ly associated and are listed in the preterm birth database and include
hypertrophic cardiomyopathy, the mTOR signaling pathway and
prostate cancer. Also of note, the IGF1R was identiﬁed in the preterm
birth database as associated with preterm birth. This was the result of
a large linkage analysis done in the Finnish population [36]. In the lat-
ter report, the association of IGF1Rwith preterm birth was veriﬁed by
haplotype analysis in a larger, independent group of patients [36]. It is
likely that the failure to identify IGF1R in both our curated gene study
and the pathway analysis is due to the omission of these tag SNPs on
our genotyping platform. Nonetheless, the importance of this path-
way is suggested by our results and others [36]. IGF1 and its signaling
pathway were included in previous candidate analyses because of
their participation in the decidua-chorioamniotic, and systemic in-
ﬂammation signaling pathways which involve the PI3kinase and
mTOR signaling pathways [36], both of which were prominent in
our results.
The pathways identiﬁed in our analysis are not independent but
instead show a rich network of connectivity. This can best be seen
graphically in Fig. 3. Gephi was used to make the network maps [37].
In this ﬁgure, the blue nodes represent the shared pathways and orange
nodes those pathways only identiﬁed by dbPTB. Likewise the genes
forming the connectivity are displayed. AKT1 was the most connected
gene, being identiﬁed as contributing to a signiﬁcant role in preterm
birth in 15 pathways. This is shown in Fig. 4. A listing of the other, highly
connected dbPTB genes is provided in Supplemental Table 4. An alterna-
tive way to view the strength of the pathway analysis is not to look
solely at the gene contributing the most pathways, but to identify
Fig. 3. Network map of signiﬁcant pathways for dbPTB genes. The blue nodes represent the shared pathways and orange nodes the pathways only identiﬁed by dbPTB. Likewise the
genes (green symbols) forming the connectivity are displayed.
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and which genes were these. These results are shown in Figs. 5A and
B. Breast cancer estrogen signaling and oxidoreductase activity path-
ways each had 10 different genes contributing signiﬁcantly to their
involvement in preterm birth. The latter two pathwayswere seen solely
in the dbPTB analysis.
While our approach to pathway analysis was hypothesis-free,
inspection of the genes which showed a signiﬁcant relationship to
preterm birth reveals that several of the traditional mechanisms for
preterm birth were highly represented. This includes inﬂammation
and metabolomic disorders. Infection and inﬂammation have been
strongly linked to preterm birth [25]. Genes involved in inﬂammatory
mechanisms that emerged from the pathway analysis include: IL6,
TGFB2, NOS1, NFKB1, AKT1, IRAK1, TLR3, TLR7, TP53, IFNG, and AR.
These are all important genes, receptors and signaling elements in
inﬂammation. Many of the associations of these inﬂammatory geneswith preterm birth emerged from their involvement in other related
pathways including GSK3 signaling, small lung cell cancers, organism
processes in response to biotic stimulus and PI3K signaling, protein
serine3 kinase activity and the NFAT pathway (Fig. 3). These genes
were not identiﬁed in the only other published candidate and
pathway-based interrogation although, in the latter study, pathways
associated with inﬂammation were identiﬁed including JAK-STAT
signaling, MAP kinase signaling, T cell receptor signaling and the Toll-
like receptor signaling pathway [24].
Metabolomics has recently been identiﬁed as an emerging tech-
nology that may provide clues to the pathogenesis of preterm birth
that were not previously apparent [38,39]. In a recent report, gas
chromatography–mass spectrometry was used to proﬁle lowmolecu-
lar weight compounds in amniotic ﬂuid of patients delivering with
preterm birth with and without inter-amniotic inﬂammation [39]. A
classiﬁcation proﬁle was developed which subsequently allowed
Fig. 4. The most connected gene. AKT1 was the most connected gene, being identiﬁed as contributing to a signiﬁcant role in preterm birth in 15 pathways.
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several pathways involved in metabolomics that may provide a clue
to the genetic architecture underlying the role of metabolomics in
preterm birth. These include electron carrier activity, arginine and pro-
line metabolism, the signaling pathways involved in GSK3 and PI3K,Fig. 5. The most connected pathways. Breast cancer estrogen signaling and oxidore-
ductase activity pathways each had 10 different genes contributing signiﬁcantly to
their involvement in preterm birth. A. Breast cancer estrogen signaling. B. Oxidoreduc-
tase activity.tyrosine metabolism, response to biotic stimuli, the oxido-reductase
pathway, Fig. 5B, protein oligomerization and serine threonine kinase
activity. Of the genes associated with these pathways, the most promi-
nent were NOS1 (which is also involved in inﬂammation), protein
kinase C-alpha and ALK associated with both phosphotransferase activ-
ity alcohol group as acceptor and kinase activity and transferase activity
transferring phosphorus containing groups. The strength of our
approach can be seen through the inclusion of NOS1. NOS1 was not
identiﬁed during the literature curation process or during the aggrega-
tion of genes from transcriptome-wide arrays.NOS1was included in the
dbPTB curated genes through the pathway imputation process. Remark-
able now is the inclusion of NOS1 in multiple pathways through the
GSEA analysis. NOS1 contributed prominently to the signiﬁcance of
the smooth muscle contraction pathway, the oxidoreductase activity
pathway, arginine and proline metabolism, small lung cell cancer. In
similar fashion, AKT1 was included in the dbPTB set of curated genes
through pathway imputation. What is likewise remarkable is that
AKT1was themost frequently identiﬁed genewhose variants contribut-
ed to signiﬁcance in the pathway analysis (Fig. 4). AKT1 contributed to
identiﬁcation of signaling pathways as diverse as GSK3 signaling tight
junctions, prostate cancer, small lung cell cancer, PI3K signaling in
cardiac myocytes, telomerase pathways. AKT1 was also prominent in
the pathways that were shared between the dbPTB analysis and the
whole genome-based pathway analysis including PI3K signaling,
HSA41/50 motor signaling, eIF4 pathway, protein serine3 kinase activi-
ty, phosphotransferase activity to alcohol groups, general kinase activi-
ty, melanoma, transferase activity transferring phosphorus-containing
groups, the NFAT pathway.
We are especially interested in comparing the pathway results from
the dbPTB curated genes and the pathway results from the genome-
wide analysis. As noted above, while there were 37 shared pathways,
there were 33 signiﬁcant pathways that were only identiﬁed in the
whole genome-based pathway analysis. Prominent among these were
metabolomic pathways including phospholipase A2 activity, amino
acid derivative, biosynthetic processes, plus the pathway involving the
trans-Golgi network, enzyme inhibitor pathway, lipase activity and ni-
trogen compound biosynthetic processes and carboxyl esterase activity,
hypotaurine metabolism. In contrast, most of the pathways involving
inﬂammation were either shared or identiﬁed only by the dbPTB-
based pathway analysis. This demonstrates the strength of our hybrid
169A. Uzun et al. / Genomics 101 (2013) 163–170approach to identiﬁcation of relevant genes and pathways in complex
diseases. There have been other efforts to collate information on
preterm birth. PTBGene is a publicly available database which stores
published information on genetic associations with preterm birth [40].
The database currently includes 84 genes with 189 polymorphisms.
Using meta analyses these investigators reported 5 signiﬁcant variants.
Four of them were maternal and one was in the newborn.
In summary, we used a bioinformatically-driven strategy to
identify a parsimonious set of genes associated with preterm birth.
By aggregating genes from literature curation, publically-available
databases (most often from transcriptome-wide analysis) and then
using pathway-based imputation, we identiﬁed 617 genes for which
there was a priori biological evidence for involvement in preterm
birth. The tag SNPs associated with these genes were then used in
traditional candidate gene association testing using data from the
GENEVA genome-wide association study. While we increased our
power by focusing on a smaller number of comparisons, none of the
identiﬁed single gene variance reached statistical signiﬁcance. We
did, however, corroborate the best of those curated genes, IGF1 in
the pathway-based analyses in both the dbPTB pathway analysis and
the genome-wide analysis. The database for preterm birth was built
to support analysis of gene/gene interactions. It is clear using
extremely large sets of SNPs that it's computationally expensive to
carry out even pair-wise comparisons of genes. Moreover, the
knowledge-based association of genetic variation with disease dic-
tates that all variants are not interacting with each other. Rather,
gene/gene interactions occur on the basis of known biological infor-
mation. This body of information has been built into robust databases
including KEGG, Biocarta, DAVID, GO and Ingenuity [41]. Although
pathway-based analysis methods help us in understanding and eval-
uating GWAS data, improvements are forthcoming. Better summary
statistics will help to evaluate the results more robustly as described
in Wang et al. [33]. Likewise, gene level P-values which usually
depend on SNP association test are limited by the number and prefer-
ence of SNPs on the arrays. Another limitation is to identify which
SNP is the best representative of a given gene by considering not
only the best association P-values but also the combined effects of
SNPs in linkage disequilibrium [33].
The gene set enrichment approach allowed us to interrogate the
known biological associations annotated by several of these data-
bases. By permutation testing, we compared the association of the
single nucleotide polymorphisms tagging the genes in our dataset
and their association in cases and controls. Even given the anticipated
improvements in pathway-based methods, the results were extraor-
dinary. We identiﬁed a large number of signiﬁcant pathways in
which biologically relevant curated genes and their associated vari-
ants showed signiﬁcant segregation between the preterm birth and
full term births. Moreover, the curated genes from the dbPTB dataset
gave much stronger associations than the genome wide analysis in
all but a few of these pathways. These results provide important con-
ﬁrmation of the role of genetic architecture in the risk of preterm
birth. They also provide important mechanistic insights and curated
genes which are suitable for future genetic association testing or
ideal targets for more thorough evaluation including targeted
re-sequencing. We recognize that, due to the lack of a replication
dataset, this study should be considered hypothesis generating and
that these results will need to be replicated in an appropriate dataset.4. Materials and methods
4.1. dbPTB; the database for preterm birth
We identiﬁed 186 genes using the literature-based curation, 215
genes from publically-available databases and an additional 216
genes from the pathway-based interpolation [28]. These 617 genesrepresent a robust set of genes for which there is good prior biological
evidence for involvement in preterm birth [28].
4.2. The Gene Environment Association Studies initiative (GENEVA) data
We analyzed the single nucleotide polymorphism (SNP) genotyping
data from a prospective cohort study in Denmark. The data were
derived from the Gene Environment Association Studies initiative
(GENEVA) funded by the trans-NIH Genes, Environment, and Health
Initiative (GEI) [42]. The data from GENEVA consist of approximately
4000Danishwomen and children and include phenotype and genotype
information from a genome-wide case/control study using approxi-
mately 1000 preterm mother–child pairs. There is also data from 1000
control mother–child pairs where the child was born greater than or
equal to 38 weeks of gestation. All data were deposited into the Data-
base for Genotypes and Phenotypes (dbGaP) [29]. Genome wide SNP
genotyping was performed using Illumina Human 660 W-Quad_v1_A
(n=560,768 SNPs) at the Center for Inherited Disease Research,
Baltimore, MD. As reported in the data set release, genotypes were not
reported for any SNP which had a call rate less than 85% or which had
more than 1 replicate error as deﬁned with the HapMap control
samples.
4.3. SNP association testing in PLINK
We ran basic SNP association tests in PLINK to obtain individual
marker P-values [43]. The basic association test is based on comparing
allele frequencies between cases and controls. PLINK is a free, open-
source whole genome association analysis toolset which performs a
range of basic, large-scale analyses [43]. The SNP-association analyses
were conducted in PLINK using only curated-genes from dbPTB as
well as using all the SNPs from the genome-wide analysis. For these
analyses, the study “controls” consisted of the 960 mothers who had
delivered at 38 weeks of gestation or higher. For comparison we
carried out the same curated gene analysis using three different
patient groups from the GENEVA study. We analyzed the single SNP
association with PTB by comparing the controls with the 884 patients
delivering less than 37 weeks, the 446 patients delivering less than
34 weeks, and the 92 patients delivering less than 30 weeks.
4.4. Gene set enrichment analysis
In recent years, gene set enrichment analysis (GSEA, [33]) has
become increasingly popular to support analysis of gene–gene inter-
actions and to help in understanding the individual contribution(s)
of biological pathways to genetic architecture. GSEA employs a new
way of considering the SNPs in GWAS [33]. Instead of analyzing single
SNPs individually, GSEA tests disease association with genetic
variants in functionally related genes by analyzing the genes that
belong to the same pathway which may represent the possible SNP
or gene association with complex diseases [33]. We ﬁrst performed
GSEA on GENEVA GWAS data, using the SNP P-values from the
dbPTB curated genes with i-GSEA4GWAS. The i-GSEA4GWAS web
server implements i-GSEA to explore GWAS data efﬁciently.
“i-GSEA” is an enhanced application and extension of GSEA. The pro-
gram runs the analysis in three steps. First, it maps the variants to the
genes, each gene is represented by − log (P-value) of closely spaced
SNPs in a gene. Second, i-GSEA is performed to identify the pathways
correlated to traits based on the distribution of enrichment scores
generated by permutation. FDR is calculated and used to correct for
multiple testing. The threshold of FDRb0.25 denotes the conﬁdence
of ‘possible’ or ‘hypothesis’, while the threshold of FDRb0.05 is
regarded as ‘high conﬁdence’ or ‘with statistical signiﬁcance’. Finally,
the program lists signiﬁcant pathways, the genes within those path-
ways which contributed to the signiﬁcant associations along with
the SNPs that contributed to the association.
170 A. Uzun et al. / Genomics 101 (2013) 163–170Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.ygeno.2012.12.005.
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